文献速递前列腺癌

AFU-GETUG-20随机III期试验:高危局限性前列腺癌根治术后辅助亮丙瑞林治疗结果

Results of the Randomized Phase 3 AFU-GETUG-20 Trial Evaluating Adjuvant Leuprorelin Acetate After Radical Prostatectomy in Men with High-risk Localized Prostate Cancer.
PubMed 文献 · Eur Urol Oncol · 2026-01-03

AFU-GETUG-20开放标签随机III期试验在37家法国中心纳入325例根治术后Gleason≥7且PSA<0.1 ng/ml的非转移性高危前列腺癌患者,1:1随机接受观察或亮丙瑞林(45 mg皮下每6月,共24月)治疗。10年转移风险两组相似(HR 0.63,95%CI 0.30-1.30,p=0.204),但亮丙瑞林组不良事件增加、生活质量更差。

要点

  • 高危局限性前列腺癌根治术后PSA<0.1 ng/ml者,辅助亮丙瑞林未改善无转移生存。
  • 亮丙瑞林组总体健康恶化、疲劳、疼痛更早出现,潮热等不良事件显著增加。
  • 该人群术后立即雄激素剥夺治疗不推荐,应权衡不良反应与生活质量。

核心结论

  • 高危非转移性前列腺癌患者根治术后PSA不可测时,立即使用亮丙瑞林不改善生存,反而增加不良事件并降低生活质量。

研究设计与样本

  • 开放标签随机III期试验,37家法国中心,2011-2017年纳入325例根治术后Gleason≥7且PSA<0.1 ng/ml的非转移性前列腺癌患者,1:1随机至观察组(n=163)或亮丙瑞林组(n=162)。
  • 亮丙瑞林方案为45 mg皮下注射每6月一次,持续24个月;主要终点为意向治疗人群(n=322)的无转移生存。

主要发现

  • 10年转移风险两组相似:HR 0.63(95%CI 0.30-1.30),p=0.204。
  • 无PSA升高生存(HR 0.74,95%CI 0.47-1.16,p=0.187)、总生存(HR 1.24,95%CI 0.56-2.76,p=0.596)和前列腺癌特异性生存(HR 0.57,95%CI 0.10-3.17,p=0.512)均无显著差异。
  • 亮丙瑞林组术后睾酮水平更低(p<0.001),总体健康恶化时间更短(p=0.0019),疲劳(p<0.001)和疼痛(p<0.001)更早出现。
  • 不良事件增加:潮热83.6% vs 6.2%,疼痛57.2% vs 17.1%,疲劳45.4% vs 16.3%,精神障碍25.0% vs 2.3%。

临床怎么用

  • 对于根治术后PSA<0.1 ng/ml的高危局限性前列腺癌患者,不应常规立即给予亮丙瑞林辅助治疗。
  • 临床决策应充分告知患者辅助雄激素剥夺治疗缺乏生存获益且可能降低生活质量。

局限性

  • 入组不足影响试验把握度,但允许进行相关比较。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Androgen-deprivation therapy survival benefits after radical prostatectomy (RP) in nonmetastatic high-risk prostate cancer (PCa) patients with an undetectable prostate-specific antigen (PSA) level are unclear. The AFU-GETUG-20 study assessed the benefit of leuprorelin immediately after RP in this population. METHODS: This open-label, randomized, phase 3 trial is conducted at 37 French centers. Participants undergoing RP for nonmetastatic PCa were aged ≥18 yr, with a postoperative Gleason score of ≥7 and PSA <0.1 ng/ml. Participants were randomly assigned (1:1) to the observation or leuprorelin (45 mg subcutaneous Q6M, 24 mo) arm. The primary endpoint was metastasis-free survival in the intent-to-treat population (n = 322). The secondary objectives PSA and testosterone level evolution, PCa-specific survival, overall survival, safety, and quality of life. KEY FINDINGS AND LIMITATIONS: From 2011 to 2017, 325 patients were randomized to the observation (n = 163) or leuprorelin (n = 162) arm. The 10-yr risk of metastasis occurrence was similar between arms (hazard ratio [HR] 0.63 [95% confidence interval {CI} 0.30-1.30]; p = 0.204) with no differences in PSA rise-free survival (HR 0.74 [95% CI 0.47-1.16]; p = 0.187), overall survival (HR 1.24 [95% CI 0.56-2.76]; p = 0.596), or PCa-specific survival (HR 0.57 [95% CI 0.10-3.17]; p = 0.512). Leuprorelin-treated patients had lower testosterone level after surgery (p < 0.001), shorter time to global health degradation (p = 0.0019), fatigue (p < 0.001), pain (p < 0.001), and additional adverse events, mainly hot flashes (83.6% vs 6.2%), pain (57.2% vs. 17.1%), fatigue (45.4% vs 16.3%), and psychiatric disorders (25.0% vs 2.3%). Insufficient enrollment affected the trial power but permitted pertinent comparison. CONCLUSIONS AND CLINICAL IMPLICATIONS: Leuprorelin treatment immediately after RP in high-risk nonmetastatic PCa patients with an undetectable PSA level does not improve survival, but increases adverse events, leading to poorer quality of life compared with observation.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Rozet F, Ruffion A, Lemercier P, et al. Results of the Randomized Phase 3 AFU-GETUG-20 Trial Evaluating Adjuvant Leuprorelin Acetate After Radical Prostatectomy in Men with High-risk Localized Prostate Cancer. Eur Urol Oncol. 2026. PMID: 41486043. doi:10.1016/j.euo.2025.11.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。